Apogee Therapeutics, Inc.
APGEDelisted Sep 3, 2026- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001974640
Apogee Therapeutics, Inc. was delisted on Sep 3, 2026; its insiders filed their last Form 4 on Sep 3, 2026; 289 institutions reported holding it in 13F filings for Q2 2026, worth $8.93B in total; Soros Fund Management was the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 3:08 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K | 10-K |
| Reported | – | Mar 3, 2025 | Mar 5, 2024 |
| Operating expenses | $285.6M | $216.9M | $93.0M |
| Research and development | $214.7M | $167.9M | $68.4M |
| Selling, general and administrative | $70.9M | $49.0M | $24.6M |
| Operating income | -$285.6M | -$216.9M | -$93.0M |
| Income tax | $278.0K | $18.0K | $0 |
| Net income | -$255.8M | -$182.1M | -$84.0M |
| EPS, basic | $-4.22 | $-3.30 | $-3.36 |
| EPS, diluted | $-4.22 | $-3.30 | $-3.36 |
| Weighted shares, basic | 60.7M | 55.2M | 25.0M |
| Weighted shares, diluted | 60.7M | 55.2M | 25.0M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K | 10-K |
| Reported | – | Mar 3, 2025 | Mar 5, 2024 |
| Cash and equivalents | $131.5M | $141.8M | $118.3M |
| Short-term investments | $598.6M | $378.9M | $277.1M |
| Total current assets | $741.4M | $529.7M | $398.4M |
| Property, plant and equipment | $5.69M | $1.96M | $377.0K |
| Total assets | $937.1M | $754.0M | $401.4M |
| Accounts payable | $1.22M | $1.07M | $2.14M |
| Total current liabilities | $27.9M | $28.6M | $20.6M |
| Total liabilities | $33.3M | $37.2M | $21.5M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K | 10-K |
| Reported | – | Mar 3, 2025 | Mar 5, 2024 |
| Operating cash flow | -$227.4M | -$171.2M | -$74.8M |
| Capital expenditures | $5.15M | $1.15M | $167.0K |
| Free cash flow | -$232.6M | -$172.3M | -$74.9M |
| Stock-based compensation | $46.3M | $23.3M | $6.10M |
| Investing cash flow | -$179.6M | -$300.5M | -$273.9M |
| Financing cash flow | $396.5M | $495.1M | $315.4M |
| Net change in cash | -$10.5M | $23.5M | -$33.3M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Apogee Therapeutics, Inc. reports no single share count on its 10-K and 10-Q covers. Companies with several share classes report one count per class, which this data doesn't include.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.